<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04183153</url>
  </required_header>
  <id_info>
    <org_study_id>53928</org_study_id>
    <nct_id>NCT04183153</nct_id>
  </id_info>
  <brief_title>Neuroendocrine Mapping of the Cerebral Cortex</brief_title>
  <official_title>Endo-Connectome Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is investigating brain regions that share functional connectivity with the&#xD;
      hypothalamus and the stimulation of those regions using repetitive transcranial magnetic&#xD;
      stimulation (rTMS) to activate the hypothalamus indirectly. The goal of this study is to&#xD;
      determine the effectiveness of rTMS in influencing the hypothalamus to better understand the&#xD;
      mechanisms between it and the neuroendocrine processes it controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Principal Investigator left lab&#xD;
  </why_stopped>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma GnRH levels resulting from hypothalamus activation via LC-MS</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure levels of the gonadotropin-releasing hormone (GnRH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma vasopressin levels via LC-MS</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure levels of the vasopressin hormone in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma oxytocin levels via LC-MS</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure levels of the oxytocin hormone in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma TRH levels via LC-MS</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure levels of the thyrotropin-releasing hormone (TRH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma CRH levels via LC-MS</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure levels of the corticotropin-releasing hormone (CRH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma somatostatin levels via LC-MS</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure levels of the somatostatin hormone, or growth hormone-inhibiting hormone (GHIH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PRLH levels via LC-MS</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure levels of the prolactin-releasing hormone (PRLH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma FSH levels via LC-MS</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure levels of the follicle-stimulating hormone (FSH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma LH levels via LC-MS</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure levels of the luteinizing hormone (LH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma ACTH levels via LC-MS</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure levels of the adrenocorticotropic hormone (ACTH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma cortisol levels via LC-MS</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure levels of the cortisol hormone in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure via sphygmomanometer</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure systolic and diastolic blood pressure (BP) with a sphygmomanometer as a secondary measure of hypothalamic response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate via pulse oximeter</measure>
    <time_frame>3 hours</time_frame>
    <description>Measure heart rate (HR) with a pulse oximeter as a secondary measure of hypothalamic response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>Participants will receive repetitive transcranial magnetic stimulation (rTMS) to determine if stimulating areas with activating functional connectivity will activate the hypothalamus and in turn, have a measurable effect on hormone levels.</description>
    <arm_group_label>Healthy Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 21-55&#xD;
&#xD;
          -  Gender: Females and Males&#xD;
&#xD;
          -  Weight: Less than 280 pounds&#xD;
&#xD;
          -  Mobile&#xD;
&#xD;
          -  Normal vision with corrective lenses if necessary&#xD;
&#xD;
          -  Fluent in English (written and spoken)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of epilepsy/seizures (including history of withdrawal/provoked seizures)&#xD;
&#xD;
          -  Metal implant in brains (e.g. deep stimulation), cardiac pacemaker, or cochlear&#xD;
             implants&#xD;
&#xD;
          -  Shrapnel or any ferromagnetic item in the head&#xD;
&#xD;
          -  Showing symptoms of withdrawal from alcohol or benzodiazepines&#xD;
&#xD;
          -  Current severe insomnia (must sleep a minimum of 4 hours the night before stimulation)&#xD;
&#xD;
          -  Migraine or significant headaches&#xD;
&#xD;
          -  Shoulder or neck stiffness&#xD;
&#xD;
          -  Over 280 pounds&#xD;
&#xD;
          -  In-dwelling ferrous metals&#xD;
&#xD;
          -  Left handed&#xD;
&#xD;
          -  Abnormal hearing&#xD;
&#xD;
          -  Abnormal vision that cannot be corrected with lenses&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Illicit drug use&#xD;
&#xD;
          -  Psychotropic medication use&#xD;
&#xD;
          -  Marijuana and/or nicotine use&#xD;
&#xD;
          -  Psychiatric or neurological conditions&#xD;
&#xD;
          -  Endocrine conditions&#xD;
&#xD;
          -  History of head trauma with loss of consciousness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Sudheimer, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

